Literature DB >> 22586796

Advances in the treatment of melanoma.

Katie E Lacy1, Sophia N Karagiannis, Frank O Nestle.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22586796      PMCID： PMC4954106          DOI： 10.7861/clinmedicine.12-2-168

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


× No keyword cloud information.
  13 in total

1.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

Authors:  Paul B Chapman; Axel Hauschild; Caroline Robert; John B Haanen; Paolo Ascierto; James Larkin; Reinhard Dummer; Claus Garbe; Alessandro Testori; Michele Maio; David Hogg; Paul Lorigan; Celeste Lebbe; Thomas Jouary; Dirk Schadendorf; Antoni Ribas; Steven J O'Day; Jeffrey A Sosman; John M Kirkwood; Alexander M M Eggermont; Brigitte Dreno; Keith Nolop; Jiang Li; Betty Nelson; Jeannie Hou; Richard J Lee; Keith T Flaherty; Grant A McArthur
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

Authors:  Michele Del Vecchio; Roberta Mortarini; Stefania Canova; Lorenza Di Guardo; Nicola Pimpinelli; Mario R Sertoli; Davide Bedognetti; Paola Queirolo; Paola Morosini; Tania Perrone; Emilio Bajetta; Andrea Anichini
Journal:  Clin Cancer Res       Date:  2010-10-28       Impact factor: 12.531

Review 4.  Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review.

Authors:  Teresa Petrella; Ian Quirt; Shailendra Verma; Adam E Haynes; Manya Charette; Kate Bak
Journal:  Cancer Treat Rev       Date:  2007-06-11       Impact factor: 12.111

5.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

6.  Somatic activation of KIT in distinct subtypes of melanoma.

Authors:  John A Curtin; Klaus Busam; Daniel Pinkel; Boris C Bastian
Journal:  J Clin Oncol       Date:  2006-08-14       Impact factor: 44.544

7.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

8.  Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.

Authors:  Neil N Senzer; Howard L Kaufman; Thomas Amatruda; Mike Nemunaitis; Tony Reid; Gregory Daniels; Rene Gonzalez; John Glaspy; Eric Whitman; Kevin Harrington; Howard Goldsweig; Tracey Marshall; Colin Love; Robert Coffin; John J Nemunaitis
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

9.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

Authors:  Alexander M M Eggermont; Stefan Suciu; Mario Santinami; Alessandro Testori; Wim H J Kruit; Jeremy Marsden; Cornelis J A Punt; François Salès; Martin Gore; Rona Mackie; Zvonko Kusic; Reinhard Dummer; Axel Hauschild; Elena Musat; Alain Spatz; Ulrich Keilholz
Journal:  Lancet       Date:  2008-07-12       Impact factor: 79.321

10.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544
View more
  3 in total

Review 1.  Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.

Authors:  Nigel Fleeman; Adrian Bagust; Sophie Beale; Angela Boland; Rumona Dickson; Kerry Dwan; Marty Richardson; Yenal Dundar; Helen Davis; Lindsay Banks
Journal:  Pharmacoeconomics       Date:  2015-09       Impact factor: 4.981

2.  Euphorbia fischeriana Steud inhibits malignant melanoma via modulation of the phosphoinositide-3-kinase/Akt signaling pathway.

Authors:  Meng-Hua Dong; Qian Zhang; Yuan-Yuan Wang; Bai-Sui Zhou; Yu-Fei Sun; Qiang Fu
Journal:  Exp Ther Med       Date:  2016-02-09       Impact factor: 2.447

Review 3.  Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).

Authors:  Sadek Malas; Micaela Harrasser; Katie E Lacy; Sophia N Karagiannis
Journal:  Oncol Rep       Date:  2014-06-20       Impact factor: 3.906
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.